US Drug Shortages In COVID-19 Era: A Domestic Problem With Domestic Solutions
Executive Summary
Rather than rail at China, senators explored causes and corrective actions for drug shortages that are closer to home.
You may also be interested in...
India Steps Up Scrutiny After Chinese API Prices, Military Tensions Rise
A recent military skirmish with China and a 35-40% average increase in prices of drug raw materials has seen India step up scrutiny of imports from the country. While the industry is seeking a hike in domestic formulations prices, product shortages are not expected in the short term.
US FDA And Congress: Criticism Of Leadership Ramping Up, But Bipartisan Truce Holds For Now
Senate Finance Committee’s hearing on FDA’s overseas inspection program suggests that agency’s status as a rare focus for bipartisan support amid the Trump Presidency is getting more tenuous – but still holding for the time being.
The Quality Lowdown: ICH Q9, FDA QMM, THC Impurities And Recertified MAPPs
Alphabet soup of policy developments includes an answer to subjectivity in risk assessment, the unexpected industry benefit of the FDA’s quality rating plans, and some advice on testing for impurities that could be controlled substances.